NRAS and Miyoshi myopathy: ASH 2024 and EHA 2025 highlighted Circio’s TG01 mutant RAS vaccine showing early clinical benefit, including stable disease or better in ~50% of evaluatable patients with high-risk SMM or MM harboring KRAS/NRAS mutations (interim Phase 1/2 data, NCT05841550) [55,56].